Of note this is where a lot or AVR's staff overhead cuts appear to have occurred when we pivoted from the previous IV/product sales company into a product development company a few years ago. It takes a lot of man/woman power to market and sell to big corporations like hospitals/clinics. At least to practitioners it's individual reps who build the relationships, and it's the practitioners that set the device/tool preference that in turn get supplied to hospitals for procedures, not other management non-clinical heads. This is where being the best device in the business gets us into patients - in most specialties I'd say this is a slow process like orthopaedics where all cements/prosthetics are larger comparable.
I really think we are leaps and bounds beyond the competition and cardiologists are pretty savvy. Though I doubt this will be our problem to worry about . Ramble over
- Forums
- ASX - By Stock
- Ann: DurAVR First In Human Patient 6 Month Study Follow Up
Of note this is where a lot or AVR's staff overhead cuts...
- There are more pages in this discussion • 27 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVR (ASX) to my watchlist
(20min delay)
|
|||||
Last
$22.25 |
Change
-0.500(2.20%) |
Mkt cap ! $427.4M |
Open | High | Low | Value | Volume |
$22.76 | $23.07 | $22.25 | $53.92K | 2.369K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 243 | $22.23 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$22.68 | 685 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 243 | 22.110 |
1 | 150 | 22.100 |
1 | 234 | 21.230 |
1 | 42 | 21.220 |
1 | 1000 | 21.120 |
Price($) | Vol. | No. |
---|---|---|
22.680 | 685 | 2 |
22.690 | 100 | 2 |
22.700 | 3000 | 1 |
23.040 | 20 | 1 |
23.050 | 1000 | 1 |
Last trade - 10.44am 29/04/2024 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |